News & Comment

Filter By:

  • With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

    • Janssen Oncology
    Advertisement Feature
  • Hayashibara is exploring the potential of the saccharide, trehalose, to advance progress in the development of new medical and therapeutic applications, with a particular focus on its ability to stabilize exosomes and improve drug delivery.

    • Hayashibara Co., Ltd. / NAGASE Group
    Advertisement Feature
  • Building on its history of successful collaborations, the global business unit at Sanofi responsible for vaccines is seeking partners with a common drive for excellence and pursuit of innovation.

    • Vaccines at Sanofi
    Advertisement Feature
  • Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

    • Synaffix
    Advertisement Feature
  • Precision diagnostics and monitoring company Oncocyte is developing the most comprehensive and rapid tumor-microenvironment gene-expression test to assess immunotherapeutic responsiveness. Combined with the company’s other tests, it provides a complete solution for cancer immunotherapy management and monitoring.

    • Oncocyte Corporation
    Advertisement Feature
  • OncXerna Therapeutics is pioneering the use of artificial intelligence (AI) in the development of drugs and biomarkers for cancer, targeting patients’ tumor microenvironment (TME) to develop a precision-medicine approach that might identify those who will benefit most from the treatments in its pipeline.

    • OncXerna Therapeutics
    Advertisement Feature
  • Marengo Therapeutics’ breakthrough discovery in T cell receptor (TCR) activation blazes a new trail for safe treatment and long-term protection against cancer.

    • Marengo Therapeutics
    Advertisement Feature
  • Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.

    • MetasTx
    Advertisement Feature
  • California-based Alamar Biosciences is beating antibodies at their own game, boosting affinity by targeting multiple epitopes on the same antigen using its Attobody platform.

    • Alamar Biosciences, Inc.
    Advertisement Feature
  • HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.

    • HOOKIPA Pharma Inc.
    Advertisement Feature
  • Recent major antibody deals involve immune checkpoint inhibitors, antibody–drug conjugates and natural killer cell engagers for cancer.

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • A novel platform that incorporates the human extracellular matrix is helping to accelerate drug development for diseases including fibrosis and solid tumors.

    • Engitix Therapeutics
    Advertisement Feature
  • A next-generation diagnostic test developed by Haystack Oncology detects the presence of micrometastatic disease in patients who have received surgery for early-stage cancer. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA—physicians can help their patients receive the appropriate type and duration of treatment and in doing so improve patient outcomes.

    • Haystack Oncology
    Advertisement Feature